Low-flow in aortic valve stenosis patients with reduced ejection fraction does not depend on left ventricular function

Svante Gersch[1,2], Torben Lange[1,2*], Bo Eric Beuthner[1,2], Manar Elkenani[1,2], Niels Paul[3], Moritz Schnelle[2,4], Javier Díez[5,6], Elisabeth Zeisberg[1,2], Miriam Puls[1,2], Gerd Hasenfuß[1,2], Andreas Schuster[1,2], Karl Toischer[1,2,7]*

[1] Department of Cardiology and Pneumology, University Medical Center Göttingen, Georg-August University, Robert-Koch-Straße 40, 37075, Göttingen, Germany

[2] German Centre for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany

[3] Department of Bioinformatics, University Medical Center Göttingen, Georg-August University, Göttingen, Germany

[4] Department of Clinical Chemistry, University Medical Center Göttingen, Georg-August University, Göttingen, Germany

[5] Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain

[6] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain

[7]Corresponding author; ktoischer@med.uni-goettingen.de

[*] these authors contributed equally

Total word count: 2989

Funding: German Research Foundation (DFG, CRC 1002, D1)

Disclosures: None

Keywords: Heart Failure with reduced ejection fraction, aortic stenosis, TAVR,

Address for correspondence:

Karl Toischer, MD
University Medical Centre Göttingen
Department of Cardiology & Pneumology
Robert-Koch-Straße 40, 37075 Göttingen, Germany
Phone: +49 551 39 66380
Fax: +49 551 39 22953
E-mail: ktoischer@med.uni-goettingen.de

Abstract:

Introduction: Patients with severe aortic stenosis (AS) and reduced left ventricular ejection fraction (LVEF) can be distinguished into high- (HG) and low-gradient (LG) subgroups. However, less is known about their characteristics and underlying (pathophysiological) hemodynamic mechanisms.

Methods:

98 AS patients with reduced LVEF were included. Subgroup characteristics were analyzed by a multimodal approach using clinical and histological data, next-generation sequencing (NGS) and applying echocardiography as well as cardiovascular magnetic resonance (CMR) imaging. Biopsy samples were analyzed with respect to fibrosis and mRNA expression profiles.

Results: 40 patients were classified as HG-AS and 58 patients as LG-AS. Severity of AS was comparable between the subgroups. Comparison of both subgroups revealed no differences in LVEF (p=0.1), LV mass (p=0.6) or end-diastolic LV diameter (p=0.12). Neither histological (HG: 23.2% vs. LG: 25.6%, p=0.73) and circulating biomarker-based assessment (HG: 2.6 ± 2.2 % vs. LG: 3.2 ± 3.1 %; p= 0.46) of myocardial fibrosis nor global gene expression patterns differed between subgroups. Mitral regurgitation (MR), atrial fibrillation (AF) and impaired right ventricular function (MR: HG: 8% vs. LG: 24%; p<0.001; AF: HG: 30% vs. LG: 51.7%; p=0.03; RVSVi: HG 36.7 vs. LG 31.1 ml/m2, p=0.045; TAPSE: HG 20.2 vs. LG 17.3 mm, p=0.002) were more frequent in LG-AS patients compared to HG-AS. These pathologies could explain the higher mortality of LG vs. HG-AS patients.

Conclusion:

In patients with low-flow severe aortic stenosis, low transaortic gradient and cardiac output are not primarily due to LV dysfunction or global changes in gene expression, but may be attributed to other additional cardiac pathologies like mitral regurgitation, atrial fibrillation or right ventricular dysfunction. These factors should also be considered during planning of aortic valve replacement.

66

67 **Abbreviations**

AF	atrial fibrillation
AS	Aortic stenosis
AVR	Aortic valve replacement
CITP	Carboxy-terminal telopeptide of collagen type I
CITP:MMP1	Ratio of serum carboxy-terminal telopeptide of collagen type I to serum matrix metalloproteinase-1
CMR	Cardiovascular magnetic resonance imaging
ECV	Extracellular volumen
HG	High gradient
LG	Low gradient
LGE	Late gadolinium enhancement
LVEDD	Left ventricular end-diastolic diameter
LVEF	left-ventricular ejection fraction
MF	Myocardial fibrosis
MMP1	matrix metalloproteinase-1
MR	mitral regurgitation
NGS	next-generation- sequencing
NT-proBNP	N-terminal pro-brain natriuretic peptide
NYHA	New York Heart Association
PICP	C-terminal propeptide of procollagen type I
Pw	Pulsed wave
RVEF	Right ventricular ejection fraction
TAPSE	Tricuspid annular plane systolic excursion
TAVI	Transcatheter aortic valve implantation

68

69 **Tables and figures**

70 Table 1 – baseline clinical characteristics

71 Table 2 – baseline electrocardiographic characteristics

72 Table 3 – baseline echocardiographic characteristics

73 Table 4 – baseline CMR-derived characteristics

74 Table 5 – Echocardiographic characteristics classified according to LV-EF </> 35%

75

Table 6 – contraction analyses of CMR-derived parameters

Supplemental Table 1 - Echocardiographic parameters assessed by transthoracic echocardiography in an all comer clinical cohort

Figure 1 Echocardiography of AS

Figure 2 – CMR imaging in AS

Figure 3 – flow chart

Figure 4 – NGS Plot

Introduction:

Aortic stenosis (AS) is the most prevalent valve disease in the ageing society.[1,2] Severe AS occurs in 3-5% of individuals over 75 years and is associated with a high burden of morbidity and mortality.[3,4] AS patients with reduced left ventricular ejection fraction (LVEF) can be subdivided in two groups: 1) AS with reduced LVEF and high transaortic gradient (Vmax >4.0m/s or PGmean >40 mmHg; HG-AS) and 2) AS with reduced LVEF and low gradient (Vmax <4.0m/s or PGmean <40 mmHg; LG-AS).

With evolving evidence, transcatheter aortic valve implantation (TAVI) has become an established treatment method of severe AS during the past decade. While current guideline clearly recommend AVR in symptomatic patients with HG-AS irrespectively from LVEF, diagnosis and treatment of LG-AS is challenging and an extended multimodal diagnostic approach is suggested in order to achieve diagnostic certainty.[5] Importantly, in a previous study, increased myocardial fibrosis (MF) in these subgroups was shown to be associated with poor outcome.[6] Moreover, LG-AS has been demonstrated to be associated with worse prognosis compared to HG-AS even after aortic valve replacement.[7,8] However, data on HG- and LG-AS phenotypes are scarce and potential underlying hemodynamic mechanisms remain unclear.

Therefore, the aim of this study was to characterize and compare patients with HG-AS and LG-AS in a multimodal approach using clinical data, echocardiography, cardiac magnetic resonance imaging, histology and next-generation- sequencing (NGS) for a more in-depth understanding of these heterogenous AS subgroups.

127 **Methods:**

128 Data for this study were gathered at the University Medical Center Göttingen. Patients were
129 classified into a high-gradient and a low-gradient group according to their transvalvular
130 gradient in echocardiography. According to current guideline recommendations HG-AS was
131 defined as a transvalvular gradient >40 mmHg or a peak aortic jet velocity Vmax > 4m/s and
132 an aortic valve area (AVA) < 1 cm^2 and LG-AS with a gradient < 40 mmHg and an AVA < 1
133 cm^2. In LG-AS group a pseudo stenosis was ruled out either by stress test and/or calcium
134 scoring in computed tomography. On admission, transthoracic echocardiography was
135 performed, a 6-minute walk test, Minnesota Living with Heart failure Quality of life
136 questionnaire (MLHFQ), New York Heart Association (NYHA) status, and N-terminal pro-brain
137 natriuretic peptide (NT-proBNP) levels were measured. Decision for TAVI was based on an
138 interdisciplinary heart team decision according to current guideline recommendations.
139 Additionally, PICP and the CITP:MMP1 ratio, which serves as an indicator of irreversible
140 myocardial fibrosis through collagen cross-linking, was analyzed. A low CITP:MMP1 ratio
141 indicates a presence of irreversible collagen deposition, while a high ratio suggests the
142 possibility of reversible collagen formation.[9] This analysis was conducted using an ELISA-
143 based assay for CITP (Orion Diagnostica, Espoo, Finland) and an alphaLISA method to
144 quantify total serum MMP-1 levels (PerkinElmer, Waltham, Massachusetts, USA) as
145 previously described.[10,11]

146 The study complied with the Principles of Helsinki and was approved by the local Ethics
147 Committee Göttingen. All patients gave written informed before study participation.

148

149 **Echocardiography:**

150 As previously described[6], all echocardiographies were performed pre-TAVI and were obtained
151 as recommended.[12] Transvalvular pressure gradient was measured by continuity equation and
152 stroke volume (SV) was computed with pulse wave Doppler signal from apical five-chamber
153 view (Figure 1). SV was then indexed to body surface area (BSA).

LV-EF was calculated by Simpson's biplane method using the manual tracing of the outline of the endocardial border on apical four and apical two-chamber view. To calculate relative wall thickness the formula (2 × posterior wall thickness/LVEDD) was used. Peak pulmonary artery systolic pressure was calculated using peak tricuspid regurgitation velocity (+ right atrial pressure). In order to validate echocardiographic findings of the study cohort, additional analyses of echocardiographic data obtained from a large clinical all-comer cohort were performed.

Next generation sequencing

The alignment, normalization and analysis of the RNA-seq data were performed using the RStudio IDE with R version 4.2.2. The raw .fastq files were aligned to the GRCh38 genome using the align function in the Rsubread R package.[13] Only uniquely mapped reads were taken into account. The Rsubread function featureCounts was used to summarize aligned reads to features of the gene annotation file taken from GenCode (Release 40).[14,15] After adding a pseudocount of 1 to all features the expression profiles were normalized to GeTMM values.[16] The functions lmFit and eBayes from the limma package were used to check for differentially expressed genes. [17,18]

Histology

After TAVI procedure, tissue samples were harvested from the basal anteroseptum in the left ventricle using biopsy forceps (Proflex-Bioptom 7F). These samples were then fixed in 10% paraformaldehyde and embedded in paraffin for further analysis. MF was evaluated in a blinded manner, using quantitative morphometry through Olympus Software cell-Sens 1.6. It was defined as the proportion of blue-stained area, indicating collagen presence, in sections of biopsy samples stained with Masson's trichrome. This proportion was determined by comparing the blue-stained area to the total tissue area.

182 **Cardiovascular magnetic resonance imaging**

183 **CMR Imaging protocol**

184 CMR imaging was performed on a 3.0-Tesla Magnetom Skyra MRI scanner (Siemens
185 Healthcare, Erlangen, Germany) using a 32-channel cardiac surface receiver coil.
186 Electrocardiography-gated balanced steady state free precession (b-SSFP) images of long-
187 axis two, three- and four-chamber views (2-, 3-, 4-CV) as well as short-axis (SAX) stacks were
188 acquired for functional myocardial assessments with the following typical image parameters:
189 25 frames per cardiac cycle, time of echo (TE) 1.5 ms, time of repetition (TR) 55 ms, flip angle
190 55°, 7 mm slice thickness with 7.7 mm inter-slice gap. Conventional 5(3)3 Modified Look-
191 Locker Inversion Recovery (MOLLI) sequences (FOV of 360 x 306.6mm^2, in-plane resolution
192 1.41 x 1.41 x 8mm^3, TR 280ms, TE 1.12ms, TI 180ms, flip angle 35°, bandwidth 1085 Hz/pixel
193 with total acquisition of 11 heart beats) for T1-mapping were performed ahead of admission of
194 a gadolinium contrast bolus (0.15 mmol/kg bodyweight) and 20 minutes after. Phase-sensitive
195 inversion-recovery-gradient echo sequences were acquired for late gadolinium enhancement
196 (LGE) analyses 15-20 minutes after the gadolinium bolus injection with the following typical
197 imaging parameters: TR 700 ms; TE 1.24 ms; flip angle 40°; slice thickness 7 mm and
198 individually adjusted inversion times typically between 300 and 400 ms) (Figure 2).

199

200 **CMR Image Analysis**

201 Based on b-SSFP images strain assessments were performed applying dedicated CMR-
202 feature tracking (CMR-FT) evaluation software (Medis Medical Imaging Systems, Leiden, The
203 Netherlands). Epi- and endocardial borders were manually delineated at end-diastole and -
204 systole in 2-, 3- and 4-CV long axis orientations to analyze global longitudinal strain (GLS).
205 Likewise, atrial endocardial contours were delineated in 2- and 4-CV images for the
206 quantification of LA reservoir (LA Es), conduit (LA Ee) and booster pump strain (LA Ea) as
207 described elsewhere.[19] For ventricular volumetric analyses epi- and endocardial borders were
208 manually delineated in SAX stacks covering the entire LV. T1-mapping based assessment of
209 extracellular volume (ECV%) reflecting myocardial tissue that is not occupied by cells was

210 conducted based on motion-corrected MOLLI sequences. The definition of ECV% was as
211 follows: ECV% = (1 – hematocrit) * [Δ R1 myocardium]/ [Δ R1 blood] according to guideline
212 recommendations.[20] In all T1 weighted images regions of interest were drawn in excluding any
213 LGE areas and careful visual reevaluation of the delineated regions was performed to avoid
214 partial volume effects due to blood pool or adjacent non-myocardial structures.[21] Using SAX
215 images of inversion recovery sequences, LGE analyses were performed by defining a 3
216 standard deviations (SD) threshold of signal intensity for the detection of ischemic and non-
217 ischemic LGE enhancement after manual epi- and endocardial border delineation as
218 previously established.[22]
219
220 **Statistical analysis**
221 Statistical analysis was performed in Graph Pad prism version 9.0. Continuous variables are
222 presented as mean ± standard deviation. Categorial data were presented as frequency and
223 percentage. Variables were tested for normal distribution by Shapiro-Wilk test. Subgroups
224 were compared by two-sided T-test, one-way analysis of variance or Mann-Whitney-U test, if
225 appropriate. For categorical variables, differences between HG- and LG-group were evaluated
226 by Fisher exact test. A p-value of <0.05 was considered statistically significant.
227

228 **Results:**

229 **Baseline characteristics**

230 98 patients with severe AS and impaired left ventricular systolic function, who were scheduled
231 for TAVI at the University Medical Center Göttingen between January 2017 and December
232 2020 were included to this study (Figure 3). 40 patients were classified as HG-AS and 58
233 patients as LG-AS (pseudo stenosis was ruled out either by stress test or calcium score
234 imaging). The mean age of the overall study population was 79.3 (± 6.8) years and participants
235 were predominantly male (75%). Cardiovascular risk factors such as dyslipidemia, arterial
236 hypertension, and diabetes mellitus were present in most of the patients (Table 1). On
237 admission, majority of the patients showed signs of cardiac decompensation coming along
238 with severe symptoms (NYHA III or IV). LG-AS patients showed no significant difference for
239 chronic coronary syndrome (HG: 65% vs. LG: 77.6%; p=0.24), but more prior coronary
240 interventions (HG: 17.5% vs. LG: 44.8%; p=0.005) or coronary artery bypass graft (CABG)
241 (HG: 2.5% vs. LG: 22.4%; p=0.007). Furthermore, atrial fibrillation (AF) occurred more
242 frequently in LG-AS patients (HG: 30% vs. LG: 51.7%; p=0.03), which also correlated with an
243 increased rate of AF on admission (HG: 12.5% vs. 41%; p=0.0029) (Table 2). Neither NT-
244 proBNP (HG: 8707 ± 9109 ng/L vs. LG: 9460 ± 14228 ng/L; p=0.3) nor the 6MWT-distances
245 differed significantly between the two subgroups. (HG: 197.9 ± 130.8 m vs. LG: 189.9 ± 118
246 m; p= 0.77). A more detailed overview of patient characteristics is presented in Table 1.

247

248 **Severity of AS and left ventricular geometry**

249 Echocardiographic characteristics are presented in Table 3. AVA was slightly smaller in HG-
250 patients compared to LG-patients. There was no difference in LVEF (HG: 37 ± 9.7% vs. LG:
251 33.9 ± 9.2%; p =0.1), LVEDD (HG: 51 ± 8.7 mm vs. LG: 54 ± 7.9 mm, p=0.12), relative wall
252 thickness (HG: 0.54 ± 0.16 vs. LG: 0.48 ± 0.12, p=0.25) or LVMI (HG: 170 ± 36.5 g/m² BSA
253 vs. LG: 166.8 ± 41.4 g/m² BSA; p=0.61). Similar results were found in CMR analyses of these
254 patients (Table 4). These echocardiographic findings were consistent in the additionally
255 analyzed all-comer cohort (Suppl. Table 1)

The lower stroke volume (HG: 66 ± 14.9 ml vs. LG: 55.6 ± 15.1 ml; p=0.001) in LG-AS patients, however, could be explained by a shorter flow duration via the stenosed aortic valve (HG: 0.35 vs. LG: 0.33; p=0.004). This indicates that despite comparable LVEF and LVEDD the left ventricle cannot generate the same pressure time integral. Characterization of the LV by CMR did not show a difference in left ventricular strain or volumes, while ECV% was significantly higher in LG-AS compared to HG-AS patients (27.1 % [26.2-29.6] vs. 25.8 [24.4-26.9], p=0.012) (Table 4).

Notably, a higher prevalence of severe mitral regurgitation (HG: 8% vs. LG: 24%; p<0.001) and an impaired right ventricular dysfunction (RVSVi: 36.7 vs. 31.1 ml/m2; p=0.045; TAPSE: 20.2 vs. 17.3mm, p=0.002) were detected in the LG-group. Furthermore, impaired hemodynamics especially affecting the right heart might be additionally indicated by regional differences in LV strain. Comparing septal vs. lateral GLS within each group revealed a significantly reduced septal GLS in the LG group (septal GLS -8.2 % vs. lateral GLS -12.7 %, p=0.008), which might be caused by raised loading pressures in the right ventricle hampering septal contractility (Table 6). In the HG group there was no difference between septal and lateral GLS (septal GLS -11.4 % vs. lateral GLS -12.0 %, p=0.22)

Histology or next-generation sequencing did not show a difference in fibrosis nor global gene expression profile (Figure 4) between HG- and LG-AS patients. Furthermore, neither PITP-levels (HG: 151 ± 33 % vs. LG: 144 ± 40 %; p= 0.58), nor CITP (HG: 10.8 ± 9.5 % vs. LG: 12.3 ± 11.9 %; p= 0.65) and CIPT/MMP1-ratio differed significantly (HG: 2.6 ± 2.2 % vs. LG: 3.2 ± 3.1 %; p= 0.46). Furthermore, CMR-derived PCWP did not differ between both groups (16.5 [14.5-21.1] vs. 19.0 [16.0-21.4], p=0.32) suggesting no difference in preload induced contractile activation according to the Frank-Starling-mechanism.

Discussion:

This study comprehensively investigated characteristics of severe HG- and LG-AS patients with reduced LVEF and there are some major findings to be considered:

1) There were no significant differences in left ventricular function and volumetric analyses.

2) No differences between subgroups were detected via histological, gene expression and circulating biomarker-based assessment.

3) Right ventricular function was significantly impaired in LG-AS patients compared to HG-AS.

4) Prevalence of atrial fibrillation and high-grade mitral regurgitation was significantly higher in LG-AS patients.

To compensate increased afterload caused by severe AS, the myocardium hypertrophes with subsequent remodeling processes leading to increased myocardial fibrosis. As the disease progresses, compensatory capabilities of the myocardium begin to fail resulting in a decrease of myocardial function.[7,23,23] Importantly, patients with severe AS and reduced LVEF have worse outcome than AS patients with preserved LVEF.[24] Nevertheless, there are two different subgroups of AS patients with reduced LVEF – one subgroup generating high transaortic pressure gradients, whereas the other group has only low pressure gradients, suggesting different left ventricular responses on pressure overload. However, there were no significant differences neither in LV function comprising strain and volumetry, nor in histological and NGS assessment between both subgroups. The only LV parameter that significantly differed was CMR-derived ECV%, which is considered as a surrogate parameter for diffuse myocardial fibrosis. Since this is in contrast to the histological and NGS findings, it remains speculative, whether these results are caused by the limitation of a local biopsy, whereas ECV% is more sensitive to detect global remodeling processes. [25] It is noteworthy, that AS is known to exhibit a characteristic diffuse myocardial fibrosis pattern.[22,26] Therefore, when evaluating myocardial fibrosis using methods like biopsy or CMR, it's crucial to account for factors like location, sampling methods, and technical analysis aspects. Invasive biopsies are limited by size and sampling precision issues, whereas LGE and ECV measurements encompass different

312 myocardial regions, providing complementary information, which should be considered when
313 interpreting the (combination of) different results and parameters.
314 In contrast, there was a significant reduction in right ventricular function (both in
315 echocardiography and CMR) in the LG-AS subgroup. Following considerations of the Frank-
316 Starling mechanism, RV dysfunction typically develops as a consequence of pressure and/or
317 volume overload. This might be caused by an impaired left heart performance, chronic lung
318 disease or pulmonary hypertension.[27] In addition, the occurrence of LV hypertrophy/LV
319 dysfunction was shown to influence RV function by a pathological downstream response to
320 pressure overload. In this context, in this study documented impaired septal GLS contraction
321 in LG-AS patients might further explain deterioration of RV function.
322 On the one hand, the current results do not show relevant differences in left heart (dys-
323)function and consequently one might speculate, whether the deterioration of RVEF is rather
324 caused by an intrinsic RV myopathy than as a mere consequence of LV failure. In line with
325 these considerations, the CMR-derived PCWP did not differ between both subgroups and,
326 therefore, potentially increased LV filling pressures might not explain an impaired RVEF and
327 rather points towards an intrinsic right heart pathology. However, especially the right ventricular
328 and atrial strain values were not reduced in the LG-AS subgroup. Since deformation
329 parameters like CMR-derived strain have been demonstrated to be even more sensitive
330 parameters to detect functional deterioration than volumetric alterations and that functional
331 changes precede myocardial geometric alterations, a fundamental RV contractile deterioration
332 cannot be demonstrated.[28,29] Therefore, a decreased RVEF might rather be caused by
333 impaired (LV and RV) hemodynamics than by a functional deterioration per se.
334 On the other hand, further explanations for altered hemodynamics and a lower transaortic
335 gradient might be comorbidities like AF or a higher prevalence of mitral regurgitation, which
336 may result in an incapability of the left ventricle to generate a higher gradient across the
337 stenotic aortic valve. Since the severity of functional MR in AS patients is often directly
338 influenced by elevated systolic ventricular pressures, this might indicate at least slight

differences in ventricular pressures/ hemodynamics that are not measurable by the applicated (non-invasive) parameters. [30–32]

Importantly, despite pathomechanistical considerations for different gradients, several studies have demonstrated substantial prognostic value both of right ventricular function and comorbidities in AS patients.[33,34] It is noteworthy that RVD has been demonstrated to be independently associated with adverse outcome after adjusting for other cardiac comorbidities.[33] However, an additional prognostic impact of cardiac comorbidities, such as AF or MR, beyond aortic stenosis and its subsequent impairment of myocardial performance has been shown in several studies. [35,36] Furthermore, comorbidities like AF have been linked with lower transaortic gradients and with adverse outcome in LG-AS patients, underlining its crucial influence on hemodynamics and prognosis in these patient cohorts. [37]

Regarding clinical implications, although guidelines and/or risk calculators include LV function or transaortic gradients for risk stratification and therapeutic decision making in AS patients, they disregard other prognostically important parameters. For example, RV function is not implemented in the EuroSCORE II and STS score despite its reported association with adverse outcome in patients undergoing TAVI. [38]

Hence, by comprehensive analyses of myocardial performance including CMR-derived right heart function as well as coexisting comorbidities, optimized timing of valve replacement and post-procedural monitoring could improve future management of AS patients undergoing TAVI. Further studies are needed to validate these findings and to transfer them into clinical practice.

Limitations:

Data were prospectively collected in our TAVI registry, without excluding comorbidities such as CAD, which makes the study population an all-comer cohort. However, the data were collected monocentrically and retrospectively queried. Furthermore, the global NGS data set showed no distinct difference when comparing the two subgroups, but we cannot exclude the possibility of significant differences within individual genes.

Conclusion:

In severe AS with reduced LVEF, patients with low transaortal gradient do not differ in left ventricular function or tissue composition compared to patients with high transaortal gradients. In contrast, right ventricular function is more restricted in the low gradient subgroup and additional cardiac comorbidities like atrial fibrillation or mitral regurgitation are more frequent than in patients with high transaortic gradients. Possessing additional important prognostic information, future diagnostic algorithms and treatment recommendations might therefore incorporate comprehensive assessment of right heart function and comorbidities for optimized treatment and patient management.

Author contributions:

SG & TL: conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft; BEB: data acquisition; ME: methodology (NGS), writing—original draft; NP: formal investigation, methodology; MS: formal analysis, data curation, writing – original draft; JD: supervision, writing; EZ: data curation; MP: data acquisition, data curation, supervision; GH: resources, supervision, writing - original draft; AS: conceptualization, project administration resources, supervision, validation; KT: conceptualization, formal analysis, investigation, methodology, project administration, resources, supervision, validation, writing - original draft. All authors read and approved the final manuscript.

Funding:

The study was funded by the German Research Foundation (DFG, SFB 1002 D04).

Data availability statement

Data are available from the corresponding author upon reasonable request.

Acknowledgments

We especially thank the study nurses Swetlana Hartmann and Kristina Schröder for study organization.

Declarations

The study was approved by the Ethics Committee of the University Medical Center Göttingen and complied with the Declaration of Helsinki. All individuals gave written informed consent before participating in the study.

References:

1. Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. *Nat Rev Cardiol*. 2011;8:162–172.

2. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde J-L, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. *Eur Heart J*. 2003;24:1231–1243.

3. Ancona' 'Roberta, Pinto' 'Salvatore Comenale. Epidemiology of aortic valve stenosis (AS) and of aortic valve incompetence (AI): is the prevalence of AS/AI similar in different parts of the world? [Internet]. [cited 2023 Jan 9];18. Available from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-18/epidemiology-of-aortic-valve-stenosis-as-and-of-aortic-valve-incompetence-ai, https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-18/epidemiology-of-aortic-valve-stenosis-as-and-of-aortic-valve-incompetence-ai

4. Bevan GH, Zidar DA, Josephson RA, Al-Kindi SG. Mortality Due to Aortic Stenosis in the United States, 2008-2017. *JAMA*. 2019;321:2236–2238.

5. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W, ESC/EACTS Scientific Document Group, ESC National Cardiac Societies. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *European Heart Journal*. 2022;43:561–632.

6. Puls M, Beuthner BE, Topci R, Vogelgesang A, Bleckmann A, Sitte M, Lange T, Backhaus SJ, Schuster A, Seidler T, Kutschka I, Toischer K, Zeisberg EM, Jacobshagen C, Hasenfuß G. Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis. *European Heart Journal*. 2020;41:1903–1914.

7. Baron SJ, Arnold SV, Herrmann HC, Holmes D, Szeto WY, Allen KB, Chhatriwalla AK, Vemulapali S, O'Brien S, Dai D, Cohen DJ. Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol*. 2016;67:2349–2358.

8. Le Ven F, Freeman M, Webb J, Clavel M-A, Wheeler M, Dumont É, Thompson C, De Larochellière R, Moss R, Doyle D, Ribeiro HB, Urena M, Nombela-Franco L, Rodés-Cabau J, Pibarot P. Impact of Low Flow on the Outcome of High-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. *Journal of the American College of Cardiology*. 2013;62:782–788.

9. Ravassa S, López B, Treibel TA, San José G, Losada-Fuentenebro B, Tapia L, Bayés-Genís A, Díez J, González A. Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies. *Mol Aspects Med*. 2023;93:101194.

10. López B, Ravassa S, González A, Zubillaga E, Bonavila C, Bergés M, Echegaray K, Beaumont J, Moreno MU, San José G, Larman M, Querejeta R, Díez J. Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. *J Am Coll Cardiol*. 2016;67:251–260.

11. Ravassa S, López B, Querejeta R, Echegaray K, San José G, Moreno MU, Beaumont FJ, González A, Díez J. Phenotyping of myocardial fibrosis in hypertensive patients with heart

failure. Influence on clinical outcome. *J Hypertens*. 2017;35:853–861.

12. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt J-U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1-39.e14.

13. Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res*. 2019;47:e47.

14. Frankish A, Diekhans M, Ferreira A-M, Johnson R, Jungreis I, Loveland J, Mudge JM, Sisu C, Wright J, Armstrong J, Barnes I, Berry A, Bignell A, Carbonell Sala S, Chrast J, Cunningham F, Di Domenico T, Donaldson S, Fiddes IT, García Girón C, Gonzalez JM, Grego T, Hardy M, Hourlier T, Hunt T, Izuogu OG, Lagarde J, Martin FJ, Martínez L, Mohanan S, Muir P, Navarro FCP, Parker A, Pei B, Pozo F, Ruffier M, Schmitt BM, Stapleton E, Suner M-M, Sycheva I, Uszczynska-Ratajczak B, Xu J, Yates A, Zerbino D, Zhang Y, Aken B, Choudhary JS, Gerstein M, Guigó R, Hubbard TJP, Kellis M, Paten B, Reymond A, Tress ML, Flicek P. GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Research*. 2019;47:D766–D773.

15. GENCODE - Human Release 40 [Internet]. [cited 2023 Jul 13];Available from: https://www.gencodegenes.org/human/release_40.html

16. Smid M, Coebergh van den Braak RRJ, van de Werken HJG, van Riet J, van Galen A, de Weerd V, van der Vlugt-Daane M, Bril SI, Lalmahomed ZS, Kloosterman WP, Wilting SM, Foekens JA, IJzermans JNM, Coene PPLO, Dekker JWT, Zimmerman DDE, Tetteroo GWM, Vles WJ, Vrijland WW, Torenbeek R, Kliffen M, Carel Meijer JH, vd Wurff AA, Martens JWM, Sieuwerts AM, on behalf of the MATCH study group. Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons. *BMC Bioinformatics*. 2018;19:236.

17. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*. 2015;43:e47.

18. Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biology*. 2014;15:R29.

19. Lange T, Schuster A. Quantification of Myocardial Deformation Applying CMR-Feature-Tracking—All About the Left Ventricle? *Curr Heart Fail Rep*. 2021;18:225–239.

20. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, Ugander M, van Heeswijk RB, Friedrich MG. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). *Journal of Cardiovascular Magnetic Resonance*. 2017;19:75.

21. Backhaus SJ, Lange T, Beuthner BE, Topci R, Wang X, Kowallick JT, Lotz J, Seidler T, Toischer K, Zeisberg EM, Puls M, Jacobshagen C, Uecker M, Hasenfuß G, Schuster A. Real-time cardiovascular magnetic resonance T1 and extracellular volume fraction mapping for tissue characterisation in aortic stenosis. *Journal of Cardiovascular Magnetic Resonance*. 2020;22:46.

22. Treibel TA, López B, González A, Menacho K, Schofield RS, Ravassa S, Fontana M, White SK, DiSalvo C, Roberts N, Ashworth MT, Díez J, Moon JC. Reappraising myocardial fibrosis in

512 severe aortic stenosis: an invasive and non-invasive study in 133 patients. *European Heart*
513 *Journal*. 2018;39:699–709.

514 23. Hein S. Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded
515 Human Heart: Structural Deterioration and Compensatory Mechanisms. *Circulation*.
516 2003;107:984–991.

517 24. Ito S, Miranda WR, Nkomo VT, Connolly HM, Pislaru SV, Greason KL, Pellikka PA, Lewis
518 BR, Oh JK. Reduced Left Ventricular Ejection Fraction in Patients With Aortic Stenosis.
519 *Journal of the American College of Cardiology*. 2018;71:1313–1321.

520 25. Schulz-Menger J, Wassmuth R, Abdel-Aty H, Siegel I, Franke A, Dietz R, Friedrich MG.
521 Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular
522 magnetic resonance. *Heart*. 2006;92:399–400.

523 26. Lange T, Backhaus SJ, Beuthner BE, Topci R, Rigorth K-R, Kowallick JT, Evertz R, Schnelle
524 M, Ravassa S, Díez J, Toischer K, Seidler T, Puls M, Hasenfuß G, Schuster A. Functional and
525 structural reverse myocardial remodeling following transcatheter aortic valve replacement: a
526 prospective cardiovascular magnetic resonance study. *Journal of Cardiovascular Magnetic*
527 *Resonance*. 2022;24:45.

528 27. Eleid MF. Right Ventricular Function in TAVR: The Right Hand Knows What the Left Hand Is
529 Doing∗. *JACC: Cardiovascular Imaging*. 2019;12:588–590.

530 28. Kim J, Yum B, Palumbo MC, Sultana R, Wright N, Das M, You C, Moskowitz CS, Levine RA,
531 Devereux RB, Weinsaft JW. Left Atrial Strain Impairment Precedes Geometric Remodeling as a
532 Marker of Post-Myocardial Infarction Diastolic Dysfunction. *JACC: Cardiovascular Imaging*.
533 2020;13:2099–2113.

534 29. DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis
535 G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global
536 longitudinal strain in patients with heart failure with preserved ejection fraction: insights from
537 the RELAX trial. *Eur J Heart Fail*. 2017;19:893–900.

538 30. Alushi B, Ensminger S, Herrmann E, Balaban Ü, Bauer T, Beckmann A, Bleiziffer S, Möllmann
539 H, Walther T, Bekeredjian R, Hamm C, Beyersdorf F, Baldus S, Boening A, Falk V, Thiele H,
540 Frerker C, Lauten A. Concomitant mitral regurgitation in patients with low-gradient aortic
541 stenosis: an analysis from the German Aortic Valve Registry. *Clin Res Cardiol*. 2022;111:1377–
542 1386.

543 31. O'Sullivan CJ, Stortecky S, Bütikofer A, Heg D, Zanchin T, Huber C, Pilgrim T, Praz F,
544 Buellesfeld L, Khattab AA, Blöchlinger S, Carrel T, Meier B, Zbinden S, Wenaweser P,
545 Windecker S. Impact of mitral regurgitation on clinical outcomes of patients with low-ejection
546 fraction, low-gradient severe aortic stenosis undergoing transcatheter aortic valve implantation.
547 *Circ Cardiovasc Interv*. 2015;8:e001895.

548 32. Freitas-Ferraz AB, Lerakis S, Barbosa Ribeiro H, Gilard M, Cavalcante JL, Makkar R,
549 Herrmann HC, Windecker S, Enriquez-Sarano M, Cheema AN, Nombela-Franco L, Amat-
550 Santos I, Muñoz-García AJ, Garcia Del Blanco B, Zajarias A, Lisko JC, Hayek S, Babaliaros V,
551 Le Ven F, Gleason TG, Chakravarty T, Szeto WY, Clavel M-A, de Agustin A, Serra V,
552 Schindler JT, Dahou A, Annabi M-S, Pelletier-Beaumont E, Pibarot P, Rodés-Cabau J. Mitral
553 Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR: Insights
554 From the TOPAS-TAVI Registry. *JACC Cardiovasc Interv*. 2020;13:567–579.

555 33. Asami M, Stortecky S, Praz F, Lanz J, Räber L, Franzone A, Piccolo R, Siontis GCM, Heg D,
556 Valgimigli M, Wenaweser P, Roost E, Windecker S, Pilgrim T. Prognostic Value of Right

557 Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement.
558 *JACC Cardiovasc Imaging*. 2019;12:577–587.

559 34. Bohbot Y, Guignant P, Rusinaru D, Kubala M, Maréchaux S, Tribouilloy C. Impact of Right
560 Ventricular Systolic Dysfunction on Outcome in Aortic Stenosis. *Circulation: Cardiovascular*
561 *Imaging*. 2020;13:e009802.

562 35. Tarantini G, Mojoli M, Windecker S, Wendler O, Lefèvre T, Saia F, Walther T, Rubino P,
563 Bartorelli AL, Napodano M, D'Onofrio A, Gerosa G, Iliceto S, Vahanian A. Prevalence and
564 Impact of Atrial Fibrillation in Patients With Severe Aortic Stenosis Undergoing Transcatheter
565 Aortic Valve Replacement: An Analysis From the SOURCE XT Prospective
566 Multicenter Registry. *JACC: Cardiovascular Interventions*. 2016;9:937–946.

567 36. Greve AM, Gerdts E, Boman K, Gohlke-Baerwolf C, Rossebø AB, Nienaber CA, Ray S,
568 Egstrup K, Pedersen TR, Køber L, Willenheimer R, Wachtell K. Prognostic importance of atrial
569 fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis
570 study. *Int J Cardiol*. 2013;166:72–76.

571 37. Kolluri N, Oguz D, Scott CG, Crestanello JA, Nkomo VT. Impact of atrial fibrillation in clinical
572 outcomes of low gradient aortic stenosis. *European Heart Journal*. 2022;43:ehac544.1617.

573 38. Koschutnik M, Dannenberg V, Nitsche C, Donà C, Siller-Matula JM, Winter M-P, Andreas M,
574 Zafar A, Bartko PE, Beitzke D, Loewe C, Aschauer S, Anvari-Pirsch A, Goliasch G,
575 Hengstenberg C, Kammerlander AA, Mascherbauer J. Right ventricular function and outcome in
576 patients undergoing transcatheter aortic valve replacement. *Eur Heart J Cardiovasc Imaging*.
577 2021;22:1295–1303.

Table 1

Parameters	HG-AS (n=40)	LG-AS (n=58)	p-value
Age (years)	79 ± 7.6	79.6 ± 6.1	0.804
Female (n)	13 (32.5)	11 (18.9)	0.154
BMI (kg/m^2)	26.2 ± 4.9	27.3 ± 5.4	0.446
BSA (m^2)	1.94 ± 0.2	1.94 ± 0.2	0.896
NYHA I	1 (2.5)	0 (-)	0.408
NYHA II	13 (32.5)	11 (18.9)	0.154
NYHA III	21 (52.5)	37 (63.7)	0.3
NYHA IV	5 (12.5)	10 (17.2)	0.581
Syncope	7 (17.5)	7 (12.0)	0.45
Signs of cardiac decompensation at admission (n)	24 (60)	38 (65.5)	0.671
Cardiac decompensation last 4 weeks (n)	14 (35)	26 (44.8)	0.404
Cardiac decompensation last 6 months (n)	4 (10)	15 (25.8)	0.069
MLHFQ (points)	33.2 ± 15.9	38.5 ± 15.2	0.111
Systolic blood pressure (mmHg)	121 ± 16.4	120 ± 15	0.920
Diastolic blood pressure (mmHg)	69 ± 12.3	66 ± 9.5	0.171
Heart rate (1/min)	72 ± 12.9	73 ± 9.5	0.432
EuroScore 2 (points)	5.0 ± 3.4	10.6 ± 10.3	**0.0002**
comobordities			
Diabetes mellitus (n)	13 (32.5)	26 (44.8)	0.294
Arterial hypertension (n)	32 (80)	52 (89.6)	0.242
Dyslipidemia (n)	23 (57.5)	36 (62)	0.679
Smoker (n)	3 (7.5)	10 (17.2)	0.229
Chronic coronary syndrome (n)	26 (65)	45 (77.5)	0.25
Prior myocardial infarction (n)	8 (20)	18 (31)	0.253
Atrial fibrillation / flutter (n)	12 (30)	30 (51.7)	**0.039**
Prior PCI (n)	7 (17.5)	26 (44.8)	**0.005**
Prior CABG (n)	1 (2.5)	13 (22.4)	**0.007**
Aortic valve replacement (n)	0 (-)	1 (1.7)	>0.999
TAVI (n)	0 (-)	2 (3.4)	>0.999
Pacemaker / ICD (n)	6 (15)	15 (25.8)	0.222
Peripheral vascular disease (n)	3 (7.5)	15 (25.8)	**0.032**
eAVK (n)	6 (15)	22 (37.9)	**0.022**
Prior cerebral ischaemia event (n)	4 (10)	12 (20.6)	0.179
COPD (n)	2 (5)	12 (20.6)	0.039
CHA_2DS_2-VASc-Score (points)	5 ± 1.2	5.5 ± 1.3	0.065

Parameters	HG-AS (n=40)	LG-AS (n=58)	p-value
6-minute walk test, (meters)	197.9 ± 130.8	189.9 ± 118	0.767
medication			
angiotensin converting enzyme inhibitor (n)	21 (52.5)	26 (44)	0.539
Angiotensin II receptor antagonist (n)	7 (17.5)	14 (24.1)	0.465
Sacubitril/Valsartan (n)	1 (2.5)	5 (8.6)	0.396
betablocker (n)	27 (67.5)	41 (70.6)	0.8
aldosterone antagonist (n)	13 (32.5)	18 (31.0)	>0.999
loop diuretic (n)	23 (57.5)	42 (72.4)	0.135
thiazide (n)	9 (22.5)	11 (18.9)	0.799
amiodarone (n)	1 (2.5)	3 (5.1)	0.643
statine (n)	24 (60)	38 (65.5)	0.671
aspirin (n)	22 (55)	34 (58.6)	0.836
Vitamin K antagonist (n)	6 (15)	13 (22.4)	0.441
NOAC (n)	5 (12.5)	10 (17.2)	0.581
laboratory			
haemoglobin (g/dl)	12.5 ± 1.7	12.5 ± 2.01	0.9
NT-proBNP (ng/L)	8707 ± 9109	9460 ± 14228	0.3
Creatinine (mg/dl)	1.22 ± 0.78	1.49 ± 1.29	0.004
MDRD (ml/min/1.73 m^2)	62.5 ± 19.2	54.7 ± 22.1	0.1

Baseline characteristics of the study cohort. Continuous variables are expressed as mean ± standard deviation, categorical data are represented as frequency and percentage. Differences between both groups were tested with two-sided t-Test or Mann-Whitney-U test.
BMI: body mass index; BSA: body surface area; CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; MDRD: Modification of Diet in Renal Disease; ICD: Implantable Cardioverter Defibrillator; MLHFQ: Minnesota living with heart failure questionnaire; NOAC: non-vitamin K antagonist anticoagulant NT-proBNP: B-type natriuretic Peptide; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; TAVI: Transcatheter aortic valve implantation

Table 2: ECG characteristics

Parameters	HG-AS (n=40)	LG-AS (n=56)	p-value
QRS duration	120 ± 35	127 ± 31	0.3
Sinusrhythm at admission	31 (77.5)	27 (48)	0.006
Afib/-flutter at admission	5 (12.5)	23 (41)	0.003
RBBB	3 (7.5)	10 (18)	0.22
LBBB	3 (7.5)	9 (16)	0.35
intraventricular (non-LBBB, non-RBBB)	11 (27.5)	10 (18)	0.32

ECG parameters of the study cohort. Continuous variables are expressed as mean ± standard deviation, categorical data are represented as frequency and percentage. Afib: atrial fibrillation; LBBB: left bundle branch block; RBBB: right bundle branch block

Table 3: Echocardiographic characteristics

	HG-AS (n=39)	**LG-AS** (n=58)	**(p-value)**
BSA (m²)	1.9 ± 0.2	1.9 ± 0.2	0.99
LVEF nS (%)	37 ± 10	33.9 ± 9	0.10
LVEDV (ml)	119 ± 39	122 ± 46	0.71
LVESV (ml)	76 ± 33	83 ± 40	0.39
SVI mD (ml/m^2 BSA)	34.4 ± 8.4	28.6 ± 6.9	**0.0007**
LVEDD (mm)	51 ± 8.7	54 ± 7.9	0.12
LVESD (mm)	42 ± 9.0	45 ± 7.9	0.13
IVS (mm)	15 ± 2.1	14 ± 2.7	**0.03**
PWT (mm)	13 ± 2.4	13 ± 2.4	0.15
LVMI (g/m² BSA)	170 ± 36	166 ± 41	0.61
RWT	0.54 ± 0.16	0.48 ± 0.12	0.25
Vmax (m/s)	4.4 ± 0.4	3.2 ± 0.4	**<0.0001**
PGmean (mmHg)	47 ± 9	24 ± 6	**<0.0001**
aortic valve area (cm^2)	0.61 ± 0.2	0.7 ± 0.2	**0.0001**
LAVI (ml/m^2 BSA)	54.7 ± 18	53 ± 17	0.83
TAPSE (mm)	20.2 ± 5.0	17.3 ± 3.7	**0.0019**
PAP systolic (mmHg)	52 ± 16	47 ± 12	0.13
AR I (n)	19 (49)	25 (43)	0.53
AR II (n)	16 (41)	17	0.28
AR III (n)	0 (0)	0 (0)	>0.999
MR I (n)	21 (54)	17 (29.3)	**0.02**
MR II (n)	15 (38)	27 (47)	0.4
MR III (n)	3 (8)	14 (24)	**<0.0001**
TR I (n)	22 (56)	30 (52)	0.68
TR II (n)	11 (28)	20 (34)	0.65
TR III (n)	2 (5)	5 (9)	0.69
Stroke volume (ml)	66 ± 14.9	55.6 ± 15.1	**0.001**
Duration of the flow (ms)	0.35 ± 0.03	0.33 ± 0.03	**0.004**
Mitral regurgitation volume (ml)	26.7 ± 11.3	32.1 ± 17.6	0.2
SV/ duration of the flow (ml/ms)	186 ± 44	165 ± 42	**0.027**
SV/ mitral regurgitation volume	2.7 ± 1.1	2.2 ± 1.2	0.12
SV/ mitral regurgitation volume	2.7 ± 1.1	2.2 ± 1.2	0.12
cardiac output (ml/min)	4.7 ± 1.2	4.0 ± 1.3	0.16

Echocardiographic parameters of the study cohort. Continuous variables are expressed as mean ± standard deviation; categorical data are represented as frequency and percentage. AI: aortic regurgitation; BSA: body surface area; LVEF: ejection fraction; IVS: intraventricular septum; LAVI: left atrial volume index; LVEDD: left ventricular end-diastolic diameter; LVEDV:

left ventricular end-diastolic volume; LVESD: left ventricular end-systolic diameter; LVESV: left ventricular end-systolic volume; LVMI: left ventricular mass index; MI: mitral regurgitation; PWT: posterior wall thickness; RWT: relative wall thickness; SV: stroke volume; SVI: stroke volume index; TAPSE: tricuspid annular plane systolic excursion; TI: tricuspid regurgitation.

Table 4: CMR characteristics

Parameter	**HG-AS** (24)	**LG-AS** (23)	p-value
niLGE volume (ml/ml²)	8.9 (5.4-14.9)	7.0 (2.7-13.7)	0.31
iLGE volume (ml/ml²)	0.0 (0.0-4.0)	0.0 (0.0-7.2)	0.84
Total LGE volume (ml/ml²)	13.2 (7.7-19.3)	7.5 (4.9-21.3)	0.35
ECV% (%)	25.8 (24.4-26.9)	27.1 (26.2-29.6)	**0.012**
LV matrix volume (ml/ml²)	21.5 (18.0-26.3)	22.1 (17.7-25.8)	0.88
LV cellular volume (ml/ml²)	65.2 (55.8-75.4)	53.3 (46.0-68.1)	0.16
Total LVMV (ml/ml²)	105.0 (90.1-117.8)	90.5 (76.1-109.6)	0.15
LVEDVi (ml/ml²)	101.5 (91.5-128.5)	105.3 (80.9-132.9)	0.8
LVESVi (ml/ml²)	58.1 (44.9-77.2)	68.2 (40.7-90.1)	0.87
LVSVi (ml/ml²)	50.4 (37.5-54.9)	40.7 (34.7-48.7)	**0.03**
RV volume (ml/ml²)	20.8 (16.7-29.8)	22.2 (18.1-26.5)	0.9
RVEDVi (ml/ml²)	72.5 (59.7-88.4)	73.3 (58.5-89.4)	0.98
RVESVi (ml/ml²)	35.6 (22.4-50.1)	41.3 (31.7-56.5)	0.31
RVSVi (ml/ml²)	36.7 (30.1-43.6)	31.1 (24.7-35.8)	**0.045**
GLS (%)	-15.6 (-12.6- -17.5)	-13.4 (-9.7- -18.3)	0.43
GLS TTP (ms)	373.4 (345.3-426.8)	370.4 (352.5-400.0)	0.83
GCS (%)	-26.7 (-18.0- -34.6)	-20.9 (-14.8- -26.3)	0.19
GRS (%)	40.1 (26.1-51.1)	39.4 (31.4-50.4)	0.87
RV GLS (%)	-23.3 (-15.8- -29.7)	-23.0 (-15.5- -26.2)	0.47
LA Es (%)	11.2 (7.8-16.6)	8.7 (6.9-12.7)	0.21
LA Ee (%)	4.4 (2.7-6.0)	3.8 (1.3-6.6)	0.67
LA Ea (%)	7.4 (4.5-9.4)	5.4 (3.9-9.5)	0.46
RVEF (%)	49.1 (38.1-62.4)	43.7 (32.2-50.8)	**0.023**
LVEF (%)	43.5 (37.3-53.1)	38.0 (28.4-48.1)	0.17
RA Es (%)	12.8 (10.1-17.4)	12.7 (8.0-14.3)	0.33
RA Ee (%)	6.1 (2.5-9.0)	4.8 (2.0-5.9)	0.14
RA Ea (%)	8.5 (5.8-11.5)	7.0 (4.2-9.3)	0.33
CMR PCWP	16.5 (14.5-21.1)	19.0 (16.0-21.4)	0.32

Cardiovascular magnetic resonance (CMR) imaging derived parameters. Variables are presented as median (interquartile range). Values of high-gradient (HG) and low-gradient (LG) aortic stenosis (AS) patients were compared using Mann-Whitney-U test. P-values in bold indicate a statistical significance.
CMR-derived characteristics of the study cohort; CMR PCWP: pulmonary capillary wedge pressure (CMR derived); ECV%: extracellular volume fraction; GCS: global circumferential strain; GLS: global longitudinal strain; GLS TTP: global longitudinal strain time to peak; GRS: global radial strain; iLGE: ischemic late-gadolinium-enhancement; LA Ea: left atrial boosterpump strain; LA Ee: left atrial conduit strain; LA Es: left atrial reservoir strain; LGE: late-gadolinium-enhancement; LVEF: left ventricular ejection fraction; LVEDVi: left ventricular end-diastolic volume index; LVESVi: left ventricular end-systolic volume index; LVSVi: left ventricular stroke volume index; niLGE: non-ischemic late-gadolinium-enhancement; RA Ea: right atrial boosterpump strain; RA Ee: right atrial conduit strain; RA Es: right atrial reservoir strain; RVEDVi: right ventricular end-diastolic volume index; RVEF: right ventricular ejection fraction; RV GLS: right ventricular global longitudinal strain; RVESVi: right ventricular end-systolic volume index;

Table 5: Echocardiographic characteristics classified according to LV-EF

	HG-AS, EF >35% (n=28)	**HG-AS, EF < 35%** (n=11)	**LG-AS, EF >35%** (n=29)	**LG-AS, EF <35%** (n=29)	**p-value**
BSA (m²)	1.9 ± 0.23	2.0 ± 0.24	1.9 ± 0.23	1.9 ± 0.21	0.17
LVEF nS (%)	42 ± 5	24 ± 6 **(a)**	42 ± 4.0	26 ± 5 **(d)**	**< 0.001**
LVEDV (ml)	106 ± 36	153 ± 32**(a)**	100 ± 27	144 ± 50 **(d)**	**< 0.001**
LVESV (ml)	61 ± 23.3	116 ± 26 **(a)**	58 ± 18	107 ± 40**(d)**	**< 0.001**
SVI mD (ml/m2 BSA)	36.8 ± 7.1	29.5 ± 5.8 **(a)**	27.4 ± 6.4	29.7 ± 7.1	**< 0.001**
LVEDD (mm)	48.5 ± 7	59.8 ± 5 **(a)**	51.2 ± 7	57.1 ± 7 **(d)**	**< 0.001**
LVESD (mm)	38.7 ± 6	52.3 ± 6 **(a)**	41.7 ± 7	48.6 ± 7 **(d)**	**< 0.001**
IVS (mm)	16.1 ± 2.2	15.0 1.9	14.7 ± 3.1	14.5 ± 2.2	0.09
PWT (mm)	13.9 ± 2.0	12.4 ± 2.4	12.6 ± 2.2	12.9 ± 2.5	0.16
LVMI (g/m² BSA)	165 ± 35	189 ± 28	154 ± 33	179 ± 44	**0.026**
Vmax (m/s)	4.52 ± 0.33	4.2 ± 0.2	3.1 ± 0.38 **(b)**	3.3 ± 0.46 **(c)**	**< 0.001**
Pmean (mmHg)	49 ± 8.3	44 ± 3.4	22.6 ± 5.89 **(b)**	26.4 ± 6.8 **(c)**	**< 0.001**
aortic valve area (cm2)	0.63 ± 0.17	0.58 ± 0.10	0.7 ± 0.15	0.77 ± 0.16 **(c)**	**0.001**
LAVI (ml/m2 BSA)	52.3 ± 16.3	61.4 ± 22.5	51.1 ± 13.5	57.0 ± 19.9	0.34
TAPSE (mm)	21.1 ± 4.9	17.7 ± 4.3	17.5 ± 4.2 **(c)**	17.0 ± 3.0	**0.032**
MI III	3 (10)	0	7 (29)	7 (29)	0.47
PAP systolic (mmHg)	49 ± 14.9	62 ± 14.4	47 ± 10.6	48 ± 14.2	0.055
regurgitation volume (mitral) (ml)	28.1 ± 11.9	22.4 ± 7.9	32.7 ± 15.3	31.7 ± 19.1	0.6
stroke volume (ml)	67 ± 14	62 ± 15.1	53 ± 15.8	58 ± 13	**0.006**
duration of the flow (ms)	0.36 ± 0.03	0.36 ± 0.03	0.33 ± 0.03	0.33 ± 0.03	**0.043**
SV/ duration of the flow (ml/ms)	190 ± 43	174 ± 45.1	158 ± 43.6	174 ± 39	0.053
SV/ mitral regurgitation volume	2.7 ± 1.1	2.5 ± 0.8	2.0 ± 1.0	2.4 1.1	0.38
cardiac output	3.9 ± 1.2	4.9 ± 1.7	3.9 ± 1.2	4.2 ± 1.2	0.07

a) HG >35 % vs. HG < 35 %; b) HG >35 % vs. LG > 35 %; c) HG <35 % vs. LG < 35 %; d)LG > 35 % vs. LG < 35 %

Echocardiographic parameter, classified according to LV-EF above and below 35%. Continuous variables are expressed as mean ± standard deviation. categorical data are represented as frequency and percentage. AI: aortic insufficiency; BSA: body surface area; LVEF: left-ventricular ejection fraction; IVS: intraventricular septum; LAVI: left atrial volume index; LVEDD: left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVESD: left ventricular end-systolic diameter; LVESV: left ventricular end-systolic volume; LVMI: left ventricular mass index; MI: mitral insufficiency; PWT: posterior wall thickness; RWT: relative wall thickness; SV: stroke volume; SVI: stroke volume index; TAPSE: tricuspid annular plane systolic excursion; TI: tricuspid insufficiency.

588 **Table 6: Comparison of septal and lateral global longitudinal strain**
589

	Septal	Lateral	p-value
HG-AS GLS	-11.4 %	-12.0 %	0.22
HG-AS GLS TTP	397 ms	385 ms	**0.03**
LG-AS GLS	-8.2 %	-12.7 %	**0.008**
LG-AS GLS TTP	366 ms	369 ms	0.49

	HG-AS	LG-AS	p-value
Septal GLS	-11.4 %	-8.2 %	0.32
Septal GLS TTP	397 ms	366 ms	0.27
Lateral GLS	-12.0 %	-12.7 %	0.63
Lateral GLS TTP	385 ms	369 ms	0.33

590
591 AS: aortic stenosis, HG: high-gradient, GLS: global longitudinal strain, LG: low-gradient, TTP:
592 time to peak.
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620

621
622 **Supplemental Table 1:** Echocardiographic parameters assessed by transthoracic
623 echocardiography in a clinical cohort
624

625

Parameter	HG-AS (116)	LG-AS (267)	p-value
EF nS (%)	34.6 ± 10	34 ± 10.3	0.61
Vmax (m/s)	4.5 ± 0.4	3.2 ± 0,4	< 0.001
Pmean (mmHg)	48.9 ± 12.6	24.4 ± 7	< 0.001
aortic valve area (cm^2)	0.58 + 0.16	0.73 ± 0.16	< 0.001
Stroke volume index	32.9 ± 9	27.7 ± 7.2	< 0.001
LVEDD (mm)	51.1 ± 8.1	51.3 ± 7.9	0.83



Figure 1: Echocardiographic images of patient with high-gradient (HG) and low-gradient (LG) aortic stenosis (AS), respectively.
Pictures in the top showing a 5-chamber view (5-CV) in end-diastole (ED) and end-systole (ES). The corresponding derived aortic valve area velocity time integral (AVA VTI) signal is shown below.



Figure 2: Cardiovascular magnetic resonance imaging in patients with high-gradient (HG) and low-gradient (LG) aortic stenosis (AS).
Myocardial function was analyzed in long-axis orientation including 4-chamber view (CV) as well as short-axis (SA) orientation. Furthermore, tissue characterization comprising calculation of extracellular volume (ECV%) and late gadolinium enhancement (LGE) was performed. ED: end-diastole; ES: end-systole.

Figure 3: Study flow chart





Figure 4: Principal component analysis (PCA) was employed to depict single LV biopsy samples obtained from individual patients. Each circle within the plot represents the projection of data from individual patient samples onto components 1 and 2, along with the percentage of total variance (x/y axis legend). Each patient's dataset is represented by two technical replicates, and any outlier replicates have been excluded (14 HG-AS and 27 LG-AS)